J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, issue.5, pp.359-86, 2015.

, Maladies chroniques et traumatismes

D. Schottenfeld and J. F. Fraumeni, Cancer epidemiology and prevention, 2006.

W. Chow, L. M. Dong, and S. S. Devesa, Epidemiology and risk factors for kidney cancer, Nat Rev Urol, vol.7, issue.5, pp.245-57, 2010.

. Esmo, Renal Cell Carcinoma: ESMO Clinical Practice Guidelines

N. B. Haas and K. L. Nathanson, Hereditary Kidney Cancer Syndromes, vol.21, pp.81-90, 2014.

K. Bensalah, L. Albiges, J. Bernhard, P. Bigot, T. Bodin et al.,

, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.28, issue.12S, pp.3-31, 2018.

H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours, Eur Urol, vol.70, issue.1, pp.93-105, 2016.

J. J. Hsieh, M. P. Purdue, S. Signoretti, C. Swanton, L. Albiges et al., Renal cell carcinoma. Nat Rev Dis Primer, vol.3, p.17009, 2009.

C. E. Kyriakopoulos, N. Chittoria, T. K. Choueiri, N. Kroeger, J. Lee et al., Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium, Clin Genitourin Cancer, vol.13, issue.2, pp.79-85, 2015.

A. R. Golshayan, S. George, D. Y. Heng, P. Elson, L. S. Wood et al., Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy, J Clin Oncol, vol.27, issue.2, pp.235-276, 2009.

. Uroweb, Professionals S-O. Renal Cell Carcinoma, 2019.

L. Zhou, X. Liu, M. Sun, X. Zhang, P. German et al., Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma, Oncogene, vol.35, issue.21, pp.2687-97, 2016.

S. Turajlic, H. Xu, K. Litchfield, A. Rowan, S. Horswell et al., Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal, Cell, vol.173, issue.3, pp.595-610, 2018.

S. P. Gonzalez, A. A. Bazan, C. Lopez, B. Bañuelos, and J. Diaz, evolution of the clinical presentation of renal cancer. fifteen years experience, Arch. Esp. Urol, vol.66, issue.6, pp.558-567, 2013.

K. L. Sunela, M. J. Kataja, and P. Kellokumpu-lehtinen, Changes in symptoms of renal cell carcinoma over four decades: changes in symptoms of rcc over four decades, BJU Int, vol.106, issue.5, pp.649-53, 2010.

I. Sarf, R. Aboutaieb, and F. Meziane, Syndrome de Stauffer associé à une tumeur rénale géante, Prog En Urol, vol.3, 2003.

, AJCC Cancer Staging Manual, 2017.

K. A. Keegan, C. W. Schupp, K. Chamie, N. J. Hellenthal, C. P. Evans et al., Histopathology in Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage, J Urol, vol.188, issue.2, pp.391-398, 2012.

K. Gupta, J. D. Miller, J. Z. Li, M. W. Russell, and C. Charbonneau, Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review, Cancer Treat Rev, vol.34, issue.3, pp.193-205, 2008.

M. Bianchi, M. Sun, C. Jeldres, S. F. Shariat, Q. Trinh et al., Distribution of metastatic sites in renal cell carcinoma: a population-based analysis, Ann Oncol, vol.23, issue.4, pp.973-80, 2012.

A. Vidart, K. Fehri, and C. Pfister, Métastases inhabituelles du cancer du rein, Ann Urol, vol.40, issue.4, pp.211-220, 2006.

B. C. Leibovich, M. L. Blute, J. C. Cheville, C. M. Lohse, I. Frank et al., SSIGN-Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials, Cancer, vol.97, issue.7, pp.1663-71, 2003.

J. Patard, H. L. Kim, J. S. Lam, F. J. Dorey, A. J. Pantuck et al., UISS-Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study, J Clin Oncol, vol.22, issue.16, pp.3316-3338, 2004.

R. J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam et al., Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, J Clin Oncol, vol.17, issue.8, pp.2530-2530, 1999.

D. Heng, W. Xie, M. M. Regan, M. A. Warren, A. R. Golshayan et al., Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.34, pp.5794-5803, 2009.

D. Y. Heng, W. Xie, M. M. Regan, L. C. Harshman, G. A. Bjarnason et al., External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol, vol.14, issue.2, pp.141-149, 2013.

S. Maclennan, M. Imamura, M. C. Lapitan, M. I. Omar, T. Lam et al., Systematic Review of Perioperative and Quality-of-life Outcomes Following Surgical Management of Localised Renal Cancer, Eur Urol, vol.62, issue.6, pp.1097-117, 2012.

. Uroweb, Professionals S-O. Renal Cell Carcinoma, 2019.

P. M. Pierorazio, M. H. Johnson, M. W. Ball, M. A. Gorin, B. J. Trock et al., Five-year Analysis of a Multi-institutional Prospective Clinical Trial of Delayed Intervention and Surveillance for Small Renal Masses: The DISSRM Registry, Eur Urol, vol.68, issue.3, pp.408-423, 2015.

A. Kutikov, R. G. Uzzo, and R. E. The, Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth, J Urol, vol.182, issue.3, pp.844-53, 2009.

A. Crestani, M. Rossanese, M. Calandriello, S. Sioletic, G. Giannarini et al., Introduction to small renal tumours and prognostic indicators, Int J Surg, vol.36, pp.495-503, 2016.

H. D. Patel, J. A. Karam, and M. E. Allaf, Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy, J Clin Oncol, 2018.

M. Gross-goupil, T. G. Kwon, M. Eto, D. Ye, H. Miyake et al., Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial, Ann Oncol, vol.29, issue.12, pp.2371-2379, 2018.

M. B. Sonbol, B. Firwana, T. Hilal, Z. Wang, D. Almader-douglas et al., Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Metaanalysis, Eur Urol Oncol, vol.1, issue.2, pp.101-109, 2018.

R. Flippot, B. Escudier, and L. Albiges, Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma, Drugs, vol.78, issue.14, pp.1443-57, 2018.

I. Park, J. Lee, J. Ahn, D. Lee, K. Lee et al., Active surveillance for metastatic or recurrent renal cell carcinoma, J Cancer Res Clin Oncol, vol.140, issue.8, pp.1421-1429, 2014.

B. I. Rini, T. B. Dorff, P. Elson, C. S. Rodriguez, D. Shepard et al., Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial, Lancet Oncol, vol.17, issue.9, pp.1317-1341, 2016.

A. Méjean, A. Ravaud, S. Thezenas, S. Colas, J. Beauval et al., Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma, N Engl J Med, vol.379, issue.5, pp.417-444, 2018.

A. Bex, L. Albiges, B. Ljungberg, K. Bensalah, S. Dabestani et al., Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma, Eur Urol, vol.74, issue.6, pp.805-814, 2018.

S. Dabestani, L. Marconi, F. Hofmann, F. Stewart, T. Lam et al., Local treatments for metastases of renal cell carcinoma: a systematic review, Lancet Oncol, vol.15, issue.12, pp.549-561, 2014.

E. Fokas, M. Henzel, K. Hamm, G. Surber, and G. Kleinert, Engenhart-Cabillic R. Radiotherapy for Brain Metastases from Renal Cell Cancer: Should Whole-Brain Radiotherapy Be Added to Stereotactic Radiosurgery?: Analysis of 88 Patients, Strahlenther Onkol, vol.186, issue.4, pp.210-217, 2010.

B. T. Welch, M. R. Callstrom, J. M. Morris, A. N. Kurup, G. D. Schmit et al., Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma, J Urol, vol.192, issue.2, pp.357-63, 2014.

C. Coppin, F. Porzsolt, M. Autenrieth, J. Kumpf, A. Coldman et al., Immunotherapy for advanced renal cell cancer, vol.56, 2008.

D. F. Mcdermott, C. G. Drake, M. Sznol, T. K. Choueiri, J. D. Powderly et al., Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab, J Clin Oncol, vol.33, issue.18, pp.2013-2033, 2015.

B. Escudier, J. Bellmunt, S. Négrier, E. Bajetta, B. Melichar et al., Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival, J Clin Oncol, vol.28, issue.13, pp.2144-50, 2010.

B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena et al., Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206, J Clin Oncol, vol.26, issue.33, pp.5422-5430, 2008.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, J Clin Oncol, vol.27, issue.22, pp.3584-90, 2009.

M. E. Gore, C. Szczylik, C. Porta, S. Bracarda, G. A. Bjarnason et al., Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial, Lancet Oncol, vol.10, issue.8, pp.757-63, 2009.

B. Escudier, C. Szczylik, S. Negrier, A. A. Desai, T. E. Hutson et al., Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, N Engl J Med, vol.10, 2007.

B. Escudier, T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard et al., Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial, J Clin Oncol, vol.27, issue.20, pp.3312-3320, 2009.

C. N. Sternberg, R. E. Hawkins, J. Wagstaff, P. Salman, J. Mardiak et al., A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update, Eur J Cancer, vol.49, issue.6, pp.1287-96, 2013.

R. J. Motzer, T. E. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma, N Engl J Med, vol.369, issue.8, pp.722-753, 2013.

B. Escudier, C. Porta, P. Bono, T. Powles, T. Eisen et al., Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study, J Clin Oncol, vol.32, issue.14, pp.1412-1420, 2014.

R. J. Motzer, B. Escudier, P. Tomczak, T. E. Hutson, M. D. Michaelson et al., Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, Lancet Oncol, vol.14, issue.6, pp.552-62, 2013.

T. E. Hutson, V. Lesovoy, S. Al-shukri, V. P. Stus, O. N. Lipatov et al., Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial, Lancet Oncol, vol.14, issue.13, pp.1287-94, 2013.

T. E. Hutson, S. Al-shukri, V. P. Stus, O. N. Lipatov, Y. Shparyk et al., Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial, Clin Genitourin Cancer, vol.15, issue.1, pp.72-78, 2017.

R. J. Motzer, D. Nosov, T. Eisen, I. Bondarenko, V. Lesovoy et al., Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial, J Clin Oncol, vol.31, issue.30, pp.3791-3800, 2013.

B. I. Rini, S. K. Pal, B. Escudier, M. B. Atkins, T. E. Hutson et al., TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), J Clin Oncol, vol.37, pp.541-541, 2019.

F. Donskov, M. D. Michaelson, I. Puzanov, M. P. Davis, G. A. Bjarnason et al., Sunitinibassociated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients, Br J Cancer, vol.113, issue.11, pp.1571-80, 2015.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet Lond Engl, vol.372, issue.9637, pp.449-56, 2008.

R. J. Motzer, B. Escudier, S. Oudard, T. E. Hutson, C. Porta et al., Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, vol.116, pp.4256-65, 2010.

G. Hudes, J. Dutcher, E. Staroslawska, I. Bodrogi, I. Schmidt-wolf et al., Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, N Engl J Med, p.11, 2007.

T. K. Choueiri, B. Escudier, T. Powles, N. M. Tannir, P. N. Mainwaring et al., Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, vol.17, issue.7, pp.917-944, 2016.

T. K. Choueiri, S. Halabi, B. L. Sanford, O. Hahn, M. D. Michaelson et al., Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.6, pp.591-598, 2017.

R. J. Motzer, T. E. Hutson, H. Glen, M. D. Michaelson, A. Molina et al., Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, vol.16, issue.15, pp.1473-82, 2015.

M. L. Dustin, The Immunological Synapse, Cancer Immunol Res, vol.2, issue.11, pp.1023-1056, 2014.

D. S. Chen and I. Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity, vol.39, issue.1, pp.1-10, 2013.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-74, 2011.

J. Haanen, I. Lugowska, C. Garassino, C. Califano, and R. , ESMO Handbook of ImmunoOncology, 2018.

P. Sharma, S. Hu-lieskovan, J. A. Wargo, and R. A. Primary, Adaptive and Acquired Resistance to Cancer Immunotherapy, Cell, vol.168, issue.4, pp.707-730, 2009.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, O. A. Frontera, B. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.378, issue.14, pp.1277-90, 2018.

A. Bex, L. Albiges, M. Staehler, K. Bensalah, R. H. Giles et al., A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations, Eur Urol, vol.74, issue.6, pp.849-51, 2018.

R. J. Motzer, T. Powles, M. B. Atkins, B. Escudier, D. F. Mcdermott et al., IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC), J Clin Oncol, vol.36, pp.578-578, 2018.

A. The and . Post, Avelumab Plus Axitinib vs Sunitinib for Advanced Kidney Cancer, vol.101, 2019.

B. I. Rini, E. R. Plimack, V. Stus, R. Gafanov, R. Hawkins et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, vol.380, issue.12, pp.1116-1143, 201921.

P. Wang, Y. Chen, S. Song, T. Wang, J. Li et al., Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis, Front Pharmacol, vol.8, p.730, 2017.

J. R. Brahmer, C. Lacchetti, B. J. Schneider, M. B. Atkins, K. J. Brassil et al., Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, vol.36, issue.17, pp.1714-68, 2018.

J. Haanen, F. Carbonnel, C. Robert, K. M. Kerr, S. Peters et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann Oncol, vol.28, issue.suppl_4, pp.119-161, 2017.

F. Martins, G. P. Sykiotis, M. Maillard, M. Fraga, C. Ribi et al., New therapeutic perspectives to manage refractory immune checkpoint-related toxicities, Lancet Oncol, vol.20, issue.1, pp.54-64, 2019.

D. Y. Wang, J. Salem, J. V. Cohen, S. Chandra, C. Menzer et al., Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, JAMA Oncol, vol.4, issue.12, pp.1721-1729, 2018.

T. Z. Horvat, N. G. Adel, T. Dang, P. Momtaz, M. A. Postow et al., Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, vol.33, issue.28, pp.3193-3201, 2015.

K. J. Williams, D. W. Grauer, D. W. Henry, and M. L. Rockey, Corticosteroids for the management of immunerelated adverse events in patients receiving checkpoint inhibitors, J Oncol Pharm Pract, p.107815521774487, 2009.

G. Talabér, M. Jondal, and S. Okret, Extra-adrenal glucocorticoid synthesis: Immune regulation and aspects on local organ homeostasis, Mol Cell Endocrinol, vol.380, issue.1-2, pp.89-98, 2013.

K. Lin and L. Wang, New dimension of glucocorticoids in cancer treatment, Steroids, vol.111, pp.84-92, 2016.

J. Galon, D. Franchimont, N. Hiroi, G. Frey, A. Boettner et al., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells, FASEB J, vol.16, issue.1, pp.61-71, 2002.

R. A. Panettieri, D. Schaafsma, Y. Amrani, C. Koziol-white, R. Ostrom et al., Non-genomic Effects of Glucocorticoids: An Updated View, Trends Pharmacol Sci, vol.40, issue.1, pp.38-49, 2019.

M. Miyata, J. Lee, S. Susuki-miyata, W. Y. Wang, H. Xu et al., Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M, Nat Commun, vol.6, p.6062, 2015.

D. W. Cain and J. A. Cidlowski, Immune regulation by glucocorticoids, Nat Rev Immunol, vol.17, issue.4, pp.233-280, 2017.

B. N. Cronstein, S. C. Kimmel, R. I. Levin, F. Martiniuk, and G. Weissmann, A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1, Proc Natl Acad Sci, vol.89, issue.21, pp.9991-9996, 1992.

Y. Cao, I. K. Bender, A. K. Konstantinidis, S. C. Shin, C. M. Jewell et al., Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans, Blood, vol.121, issue.9, pp.1553-62, 2013.

M. J. Herold, K. G. Mcpherson, and H. M. Reichardt, Glucocorticoids in T cell apoptosis and function, Cell Mol Life Sci, vol.63, issue.1, pp.60-72, 2006.

I. J. Elenkov, Glucocorticoids and the Th1/Th2 Balance, Ann N Y Acad Sci, vol.1024, issue.1, pp.138-184, 2004.

J. Dietrich, K. Rao, S. Pastorino, and S. Kesari, Corticosteroids in brain cancer patients: benefits and pitfalls, Expert Rev Clin Pharmacol, vol.4, issue.2, pp.233-275, 2011.

S. Miller, L. Mcnutt, M. Mccann, and N. Mccorry, Use of Corticosteroids for Anorexia in Palliative Medicine: A Systematic Review, J Palliat Med, vol.17, issue.4, pp.482-487, 2014.

S. Yennurajalingam and E. Bruera, Role of corticosteroids for fatigue in advanced incurable cancer: is it a 'wonder drug' or 'deal with the devil, Curr Opin Support Palliat Care, vol.8, issue.4, pp.346-51, 2014.

W. Leppert and T. Buss, The Role of Corticosteroids in the Treatment of Pain in Cancer Patients. Curr Pain Headache Rep, vol.16, pp.307-320, 2012.

A. Haywood, P. Good, S. Khan, A. Leupp, S. Jenkins-marsh et al., Corticosteroids for the management of cancer-related pain in adults, Cochrane Database Syst Rev, issue.4, p.10756, 2015.

A. J. Lawton, K. A. Lee, A. L. Cheville, M. L. Ferrone, D. Rades et al., Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review, J Clin Oncol, 2018.

P. Vayne-bossert, A. Haywood, P. Good, S. Khan, K. Rickett et al., Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev, vol.7, p.12002, 201703.

Y. Hatano, H. Matsuoka, L. Lam, and D. C. Currow, Side effects of corticosteroids in patients with advanced cancer: a systematic review. Support Care Cancer, vol.26, pp.3979-83, 2018.

A. E. Stuck, C. E. Minder, and F. J. Frey, Risk of infectious complications in patients taking glucocorticosteroids, Rev Infect Dis, vol.11, issue.6, pp.954-63, 1989.

L. Fardet, I. Petersen, and I. Nazareth, Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study. Lehman R, editor, PLOS Med, vol.13, issue.5, p.1002024, 2016.

H. Dussauze, I. Bourgault, L. Doleris, J. Prinseau, A. Baglin et al., Corticothérapie systémique et risque infectieux. Rev Médecine Interne, vol.28, pp.841-51, 2007.

R. A. Taplitz, E. B. Kennedy, E. J. Bow, J. Crews, C. Gleason et al., Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update, J Clin Oncol Off J Am Soc Clin Oncol, 2018.

R. Maxwell, A. S. Luksik, T. Garzon-muvdi, A. L. Hung, E. S. Kim et al., Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system, OncoImmunology, vol.7, issue.12, p.1500108, 2018.

A. J. Giles, M. Hutchinson, H. M. Sonnemann, J. Jung, P. E. Fecci et al.,

, Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy, J Immunother Cancer, vol.6, issue.1, p.51, 2018.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.2, pp.123-158, 2009.

A. Garant, C. Guilbault, T. Ekmekjian, Z. Greenwald, P. Murgoi et al., Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review, Crit Rev Oncol Hematol, vol.120, pp.86-92, 2017.

F. Chasset, C. Pages, L. Biard, J. Roux, I. Sidina et al., Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids, Eur J Dermatol. 20151, issue.2, pp.36-44

K. Margolin, M. S. Ernstoff, O. Hamid, D. Lawrence, D. Mcdermott et al., Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial, Lancet Oncol, vol.13, issue.5, pp.459-65, 2012.

K. C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Auclin et al., Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer, J Clin Oncol, vol.36, issue.28, pp.2872-2880, 2018.

S. C. Scott and N. A. Pennell, Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab, J Thorac Oncol, vol.13, issue.11, pp.1771-1776, 2018.

. Esmo, Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors

J. S. Weber, J. Larkin, D. Schadendorf, J. D. Wolchok, J. Wagstaff et al., Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL), J Clin Oncol, vol.35, pp.9523-9523, 2017.

S. G. Downey, J. A. Klapper, F. O. Smith, J. C. Yang, R. E. Royal et al., Prognostic Factors Related to Clinical Response in Patients with Metastatic MelanomaTreated by CTL-Associated Antigen-4 Blockade, vol.17, 2008.

D. B. Johnson, D. L. Friedman, E. Berry, I. Decker, F. Ye et al., Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Longterm Ipilimumab Survivors at a Single Referral Center, Cancer Immunol Res, vol.3, issue.5, pp.464-473, 2015.

J. C. Yang, M. Hughes, U. Kammula, R. Royal, R. M. Sherry et al., Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis, J Immunother Hagerstown Md, vol.30, issue.8, pp.825-855, 1997.

L. Albiges, S. Negrier, C. Dalban, C. Chevreau, G. Gravis et al., Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study, J Clin Oncol, vol.37, pp.542-542, 2019.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012.

T. Powles, M. Staehler, B. Ljungberg, K. Bensalah, S. E. Canfield et al., Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy, Eur Urol, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01220642

B. Escudier, P. Sharma, D. F. Mcdermott, S. George, H. J. Hammers et al., , p.25

, Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma, Eur Urol, vol.72, issue.6, pp.962-71, 2017.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, O. A. Frontera, B. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.378, issue.14, pp.1277-90, 2018.

R. J. Motzer, T. Powles, M. B. Atkins, B. Escudier, D. F. Mcdermott et al., IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC), J Clin Oncol, vol.36, pp.578-578, 2018.

B. I. Rini, E. R. Plimack, V. Stus, R. Gafanov, R. Hawkins et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, vol.380, issue.12, pp.1116-1143, 201921.

P. Wang, Y. Chen, S. Song, T. Wang, J. Li et al., Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis, Front Pharmacol, vol.8, p.730, 2017.

D. Y. Wang, J. Salem, J. V. Cohen, S. Chandra, C. Menzer et al., Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, JAMA Oncol, vol.4, issue.12, pp.1721-1729, 2018.

J. Haanen, F. Carbonnel, C. Robert, K. M. Kerr, S. Peters et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann Oncol, vol.28, issue.suppl_4, pp.119-161, 2017.

J. R. Brahmer, C. Lacchetti, B. J. Schneider, M. B. Atkins, K. J. Brassil et al., Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, vol.36, issue.17, pp.1714-68, 2018.

J. Galon, D. Franchimont, N. Hiroi, G. Frey, A. Boettner et al., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells, FASEB J, vol.16, issue.1, pp.61-71, 2002.

D. W. Cain and J. A. Cidlowski, Immune regulation by glucocorticoids, Nat Rev Immunol, vol.17, issue.4, pp.233-280, 2017.

J. Dietrich, K. Rao, S. Pastorino, and S. Kesari, Corticosteroids in brain cancer patients: benefits and pitfalls, Expert Rev Clin Pharmacol, vol.4, issue.2, pp.233-275, 2011.

A. Haywood, P. Good, S. Khan, A. Leupp, S. Jenkins-marsh et al., Corticosteroids for the management of cancer-related pain in adults, Cochrane Database Syst Rev, issue.4, p.10756, 2015.

S. Yennurajalingam and E. Bruera, Role of corticosteroids for fatigue in advanced incurable cancer: is it a 'wonder drug' or 'deal with the devil, Curr Opin Support Palliat Care, vol.8, issue.4, pp.346-51, 2014.

S. Miller, L. Mcnutt, M. Mccann, and N. Mccorry, Use of Corticosteroids for Anorexia in Palliative Medicine: A Systematic Review, J Palliat Med, vol.17, issue.4, pp.482-487, 2014.

K. C. Arbour, L. Mezquita, N. Long, H. Rizvi, E. Auclin et al., Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer, J Clin Oncol, vol.36, issue.28, pp.2872-2880, 2018.

S. C. Scott and N. A. Pennell, Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab, J Thorac Oncol, vol.13, issue.11, pp.1771-1776, 2018.

, Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors, 2018.

F. Chasset, C. Pages, L. Biard, J. Roux, I. Sidina et al., Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids, Eur J Dermatol. 20151, issue.2, pp.36-44

T. Z. Horvat, N. G. Adel, T. Dang, P. Momtaz, M. A. Postow et al., Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, vol.33, issue.28, pp.3193-3201, 2015.

A. Garant, C. Guilbault, T. Ekmekjian, Z. Greenwald, P. Murgoi et al., Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review, Crit Rev Oncol Hematol, vol.120, pp.86-92, 2017.

J. S. Weber, J. Larkin, D. Schadendorf, J. D. Wolchok, J. Wagstaff et al., Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL), J Clin Oncol, vol.35, pp.9523-9523, 2017.

J. S. Weber, F. S. Hodi, J. D. Wolchok, S. L. Topalian, D. Schadendorf et al., Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, J Clin Oncol, vol.35, issue.7, pp.785-92, 2017.

S. G. Downey, J. A. Klapper, F. O. Smith, J. C. Yang, R. E. Royal et al., Prognostic Factors Related to Clinical Response in Patients with Metastatic MelanomaTreated by CTL-Associated Antigen-4 Blockade, vol.17, 2008.

D. B. Johnson, D. L. Friedman, E. Berry, I. Decker, F. Ye et al., Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center, Cancer Immunol Res, vol.3, issue.5, pp.464-473, 2015.

R. I. Higashiyama, H. Horinouchi, K. Sekine, Y. Matsumoto, S. Murakami et al., Efficacy of nivolumab in patients treated by corticosteroid due to immune-related adverse events, J Clin Oncol, vol.36, issue.5_suppl, pp.163-163, 2018.

K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka et al., Association of ImmuneRelated Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer, JAMA Oncol, vol.4, issue.3, p.374, 2018.

M. Freeman-keller, Y. Kim, H. Cronin, A. Richards, G. Gibney et al., Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes, Clin Cancer Res, vol.22, issue.4, pp.886-94, 2016.

J. C. Osorio, A. Ni, J. E. Chaft, R. Pollina, M. K. Kasler et al., Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann Oncol Off J Eur Soc Med Oncol, vol.28, issue.3, pp.583-592, 201701.

. Teraoka, , 2019.

K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka et al., Association of ImmuneRelated Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer

D. H. Owen, L. Wei, E. M. Bertino, T. Edd, M. A. Villalona-calero et al., Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Clin Lung Cancer, 2018.

M. Kfoury, A. Voisin, M. Najean, S. Champiat, S. Laghouati et al., 1141PDAssociation between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1, Ann Oncol, 2018.

L. Albiges, S. Negrier, C. Dalban, C. Chevreau, G. Gravis et al., Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study, J Clin Oncol, vol.37, pp.542-542, 2019.

. Serment-d'hippocrate,

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les Hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses